OLA
REGN icon

Oliver Luxxe Assets’s Regeneron Pharmaceuticals REGN Stock Holding History

Oliver Luxxe Assets’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,641
Closed -$3.59M – 212
2026
Q1 		$3.59M Buy
+4,641
New +$3.55M 0.54% 67
2022
Q1 		– Sell
-7,337
Closed -$4.63M – 213
2021
Q4 		$4.63M Buy
7,337
+162
+2% +$99.6K 1.17% 22
2021
Q3 		$4.34M Buy
+7,175
New +$4.45M 1.2% 20

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Oliver Luxxe Assets's REGN Position: Q2 2026 in Review

Oliver Luxxe Assets sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 4,641 shares — an estimated $3.59M sold.

Oliver Luxxe Assets first reported a position in REGN in Q3 2021 and held it in 3 quarters. The position peaked at $4.63M in Q4 2021. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Oliver Luxxe Assets reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Oliver Luxxe Assets sold 4,641 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $3.59M.
  • Oliver Luxxe Assets first reported a position in Regeneron Pharmaceuticals in Q3 2021 and held it in 3 quarters.
  • Oliver Luxxe Assets's Regeneron Pharmaceuticals position peaked at $4.63M in Q4 2021.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Oliver Luxxe Assets's 13F filing for Q2 2026, filed 9 Jul 2026.